Crystal Meth in Milwaukee: Wisconsin’s Midwest Stimulant Market

Crystal Meth in Milwaukee: Wisconsin’s Midwest Stimulant Market

Methamphetamine remains a potent drug threat. Milwaukee is situated in the Midwest, where meth use is historically lower than in the West, but faces the rising threat of drug abuse and harms associated with co-use of high-purity methamphetamine and opioids.

Regional Usage and Sourcing

• US Context:
Treatment admissions for methamphetamine are dramatically **lower East of the Mississippi River** (less than 1%).
• Sourcing:
High-purity crystal meth is predominantly manufactured by **Mexican DTOs** in Mexico and Southern California and distributed across the country via major national corridors.
• Co-Use Threat:
The combination of meth with opioids is a severe public health concern in the Midwest.

Severe Health and Social Consequences

The harms associated with methamphetamine use are universally severe and often linked with the opioid crisis.

• Cardiovascular Damage:
Use immediately increases heart rate and blood pressure, potentially leading to stroke, heart attack, and heart failure.
• Psychosis and Paranoia:
Long-term use is linked to severe psychotic symptoms, including paranoia and hallucinations.
• Infections:
Injecting methamphetamine significantly increases the risk of acquiring and transmitting blood-borne viruses like **HIV and viral hepatitis**.

Legality and Penalties in Wisconsin (Federal)

Methamphetamine is classified as a Schedule II controlled substance under the U.S. Controlled Substances Act.

• Classification:
Methamphetamine is a **Schedule II** stimulant with a high potential for abuse.
• Trafficking Penalties:
Federal trafficking penalties are severe and quantity-based, ranging from **5 to 40 years** for a first offense involving 50 grams of pure meth or 500 grams of mixture, escalating to mandatory life imprisonment for repeat offenders with large quantities resulting in death or serious injury.